High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review

High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review

Abstract Background Nivolumab, an anti-programmed cell death-1 (PD-1) monoclonal antibody used as an immune checkpoint inhibitor, is commonly employed for its anti-tumor effects against various types of malignant tumors. However, its administration is complicated by immune-related adverse events (ir...

Full description

Bibliographic Details
Main Authors: N. Koyama, O. Iwase, E. Nakashima, K. Kishida, T. Kondo, Y. Watanabe, H. Takahashi, Y. Umebayashi, Y. Ogawa, H. Miura
Format: Article
Language:English
Published: BMC 2018-01-01
Series:BMC Pulmonary Medicine
Subjects:
Drug-induced pneumonitis
Immune checkpoint inhibitor
Nivolumab
Non-small cell lung cancer
Malignant melanoma
Hypopharyngeal carcinoma
Online Access:http://link.springer.com/article/10.1186/s12890-018-0592-x

Internet

http://link.springer.com/article/10.1186/s12890-018-0592-x

Similar Items